Minneapolis, Minnesota 55455


This is a phase I/II study of DT2219 for the treatment of relapsed or refractory CD19 (+) and/or CD 22 (+) B-lineage leukemia and lymphoma. The study consists of two phases - a phase I dose/schedule finding component using the maximum tolerated dose identified during the previous phase I study, but with a higher number of doses and a two-stage phase II extension component to confirm safety and make a preliminary determination of the activity level by disease using the dose identified in phase I.


Inclusion Criteria: - Histologic verification of B-cell lineage leukemia or B cell non-Hodgkin lymphoma and evidence of relapse/refractory disease with the presence of CD19 and/or CD22 by flow cytometry or immunohistochemistry of bone marrow aspirate, peripheral blood or node/tumor biopsy - Relapsed refractory disease that has failed conventional therapy and other therapies of higher priority - Karnofsky Performance status of ≥ 60% or, if less than 16 years of age, Lansky Play Score of ≥ 60 (appendix II) - Recovered from effects of prior therapy - Peripheral blast count under 50 x 109/L - Adequate organ function within 14 days (30 days for cardiac and pulmonary) of treatment start - Women of childbearing potential and men should be advised and agree to practice effective methods of contraception during the course of study - Voluntary written consent with appropriate parent/guardian consent and minor information sheet for participants < 18 years of age Exclusion Criteria: - Presence of leukemic or infectious pulmonary parenchymal disease - Presence of active CNS leukemia - Presence of any uncontrolled systemic infection - Documented uncontrolled seizure disorder- a seizure disorder controlled with medication - Active neurologic disorder - peripheral neuropathy alone does not exclude a patient - Active Hepatitis B or Hepatitis C (virus detectable by PCR) - Documented penicillin or cephalosporin allergies - Pregnant or lactating



Primary Contact:

Principal Investigator
Veronika Bachanova, MD, PhD
Masonic Cancer Center, University of Minnesota

Timothy Krepski, RN
Phone: 612-273-2800
Email: tkrepsk1@fairview.org

Backup Contact:


Location Contact:

Minneapolis, Minnesota 55455
United States

Timothy Krepski
Phone: 612-273-2800
Email: tkrepsk1@fairview.org

Site Status: Recruiting

Data Source: ClinicalTrials.gov

Date Processed: June 25, 2018

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.